AstraZeneca loses Symbicort patent in Europe
Executive Summary
The European Patent Office has revoked the patent covering AstraZeneca's Symbicort (formoterol/budesonide) for treatment of asthma, the company announces Oct. 18. The company does not believe the EPO decision will have an immediate impact in the EU or any impact on the U.S. or Japanese patents...